Oslo, Norway, 6 February 2026. Reference is made to the stock exchangeannouncement published 5 February 2026 by EXACT Therapeutics AS (the”Company”,Euronext Growth ticker: EXTX), a clinical-stage precision medicine company,announcing that: GE Medical Holding AB (“GEMH”), a subsidiary of GE HealthCareTechnologies Inc., confirmed that it will exercise all of its 26,973,169warrants and that remaining warrant holders therefore will have until 26February 2026 to exercise their warrants (15 business days). Reference is alsomade to the Company’s stock exchange announcement from the same day,confirmingthe exercise of warrants by certain leading shareholders and primary insidersinthe Company, that together with GEMH, represent approximately 75% of thewarrants issued.
In conjunction with the ongoing warrants exercise, the Company will host aglobal investor call (in English) on Wednesday, 11 February 2026 at 3 PMCET/9:00 AM EST. The presentation will be held by the Company’s CEO, PerWalday;CFO, John M. Edminson; and CBO, Caspar Foghsgaard. To attend the webcast, please send an email to: ca@dnbcarnegie.no. A copy of the company presentation will be made available in the Investorssection of the Company’s website.
About EXACT TherapeuticsEXACT Therapeutics is a clinical-stage precision medicine company utilizingthepower of ultrasound to activate the proprietary drug PS101 and enhance theclinical benefit of oncology therapies. PS101 has a unique mode of action andmay be combined with a wide range of therapeutic agents within oncology andacross a multitude of other indications, including brain diseases. EXACTTherapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Furtherinformation may be found here: www.exact-tx.com
For further information, please contact:Per WaldayCEO EXACT TherapeuticsEmail: per.walday@exact-tx.com
https://newsweb.oslobors.no/message/665036